Teprotumumab regulatory update

River Vision said FDA granted Orphan Drug designation to teprotumumab to treat active phase Graves' orbitopathy (thyroid eye disease). River Vision is evaluating the mAb targeting the insulin-like growth factor-1 (IGF-1) receptor in a double-blind, placebo-controlled, U.S. Phase II trial in about 84 patients with active thyroid eye disease. ...